Abstract
The effect of sizofiran (SPG) on tumor-infiltrating lymphocytes was studied in 9 patients with oral cancer. Five patients were treated and 4 served as control.
SPG was administered intramuscularly 7 days before surgery and locally 3 days before surgery. Lymphocyte subpopulations were assayed by flow cytometry for peripheral blood. Lymphocytes infiltrating into tumor tissue and cervical lymph nodes were evaluated immunohistochemically by ABC staining technique. The monoclonal antibodies employed were Leu 2a, Leu 3a, Leu 7, Leu 11b, IL-2R and Leu M3.
In the peripheral blood, CD16-positive cells increased significantly after SPG treatment. In local tumor tissue, CD4-, CD8-, CD16-, CD57-, and CD14-positive cells increased. metastatic neck lymph nodes, CD4-, CD8-, and CD25-positive cells increased.
SPG apparently enhances the immunological response of oral cancer patients in the peripheral blood, tumor tissue and metastatic cervical lymph nodes, thereby resulting in antitumor effect.
